Drug Approval | September 06, 2021
DGCI approves Hetero’s Tocilizumab
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The trial will be conducted across 10 sites in India
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
Under the new initiative, each company takes on a defined role across the recycling chain
Subscribe To Our Newsletter & Stay Updated
